This study investigated the use of monoamine oxidases as a potential biomarker for diagnosis of Alzheimer’s disease. Monoamine oxidases (MAO-A and MAO-B) play a role in the breakdown of amines as well as metabolism of neurotransmitters within the central nervous system. The most commonly used biomarkers for Alzheimer’s disease diagnosis are amyloid βeta plaques and tau tangles. However, the tests for these two biomarkers can be expensive and expose the person to radiation, thus they must be limited in its use.
Researchers from MIT used LED lights to induce gamma oscillation brain waves in mice. Studies suggest that gamma oscillations in the brain contribute to attention, perception and memory, and perhaps are impaired in Alzheimer’s disease. In mice who were genetically altered to develop Alzheimer’s, researchers stimulated the hippocampus interneurons and after an hour saw a 50% reduction in beta amyloid plaque in that area. After seeing that direct light stimulation has great effects, researchers developed a non-invasive LED light, which flickered at different frequencies.
Recent findings show that reduced bone mineral density (BMD) and osteoporosis (further progressed low BMD) rates are higher in those with Alzheimer’s disease. Studies have found that reduced BMD emerges early in the progression of Alzheimer’s disease, typically before significant cognitive deficits can be detected. Probable causation for low BMD is dysfunction in the neurotransmitter, serotonin.
November 28th was the date of the 3rd annual World Innovation Summit for Health (WISH). This 2-day summit brings together 1500 global healthcare leaders as well as ministers and senior government officials, representing over 100 countries. WISH brings together leading innovators, researchers and policy makers to foster the environment for change. These professionals come together as a community to solve global health issues.